Society partner Pfizer introduces 2017 ASPIRE Young Investigator Research Awards in Endocrinology
The mission of the 2017 Global ASPIRE Young Investigator Research Awards in Endocrinology is to advance the medical knowledge of the fundamental mechanisms of disease, mechanisms of action of current and potential future treatments, and to improve the care of patients with endocrine disorders.Pfizer invites junior investigators to apply for the 2017 Global ASPIRE Young Investigator Research Awards in Endocrinology from6 March 2017. Funding will be provided to research proposals that seek to explore translational or clinical research in the area of endocrine disease in children and young adults to address:Morbidity and mortality in Adult Growth Hormone Deficiency or AcromegalyImpact and/or needs of the patient with Growth Disorders during the pediatric and transitional years/young adult lifeNovel strategies including Quality of Life and Patient Reported Outcomes to evaluate and treat acromegaly or Adult Growth Hormone Deficiency.Early diagnosis and treatment of Adult Growth Hormone Deficiency or AcromegalyFind out more on thePfizer website.Deadline2 June 2017.Pfizer is a corporate partner of the Society for Endocrinology. See further information about our corporate supporters.
AbstractObjectiveTo determine aryl hydrocarbon interacting protein (AIP) gene variations andAIP and somatostatin receptor (SSTR) 1 –5 immunostaining in patients with apparently sporadic acromegaly with poor versus good response to somatostatin analogues (SRLs).MethodsA total of 94 patients (66 with poor and 28 with good response to SRLs) were screened for theAIP gene variations using Sanger sequencing. Immunostaining was performed in 60 tumors.ResultsSeveral variations, albeit some with undetermined significance, were detected, especially in poor responder patients. The prevalence ofAIP mutation was 2.1% in the whole...
Conclusions A telomerase expression rate greater than 10% in the pituitary tumor tissue was associated with recurrence or progression of the PA, especially in the nonfunctioning cases.
Conditions: Acromegaly; Growth Hormone Treatment; Sleep Apnea; Cardiovascular Diseases; Bone Diseases Intervention: Sponsor: University of Aarhus Recruiting
AbstractSurgery is the primary treatment for acromegaly. However, surgery may not be curative of some tumors, particularly invasive macroadenomas. Adjuvant radiation, specifically robotic stereotactic radiosurgery (rSRS), may improve the endocrine outcome. We retrospectively reviewed hormonal and radiological data of 22 acromegalic patients with invasive macroadenomas treated with rSRS at Stanford University Medical Center between 2000 and 2016. Prior to treatment, the tumor ’s median maximal diameter was 19 mm (2.5–50 mm). Cavernous sinus invasion occurred in 19 patients (86.3%) and compression of th...
Acromegaly results from the hypersecretion of growth hormone. Because of the low incidence rates of this disease worldwide, few clinical trials evaluating drug treatments have been conducted.
This study aims to identify factors affecting the timing of remission and also to quantify the rate of late remission. This is a retrospective analysis of acromegaly patients who underwent SRS between 1988 and 2016. Early and late remissions were defined based on our prior median remission time of 29 months. The median imaging and endocrine follow-ups are 66 and 104.8 months, respectively. Multivariate analysis was conducted to analyze factors leading to late remission. A total number of 157 patients, of those 102 (64.9%) patients achieved remission. of those 102 patients, 62 patie nts (60.7%) had remission in le...
ConclusionThe most important factors affecting gonadal functions, excluding central hypogonadism, are hyperprolactinemia and the duration of the indolent period before diagnosis of acromegaly. AMH levels in the majority of patients were found to be lower than the expected age. Despite the decreased ovarian reserve, fertilization and normal birth can be achieved with careful surveillance.
ConclusionsPegV and SRLs had comparable effects on VF risk in acromegaly. The activity of disease was the main determinant of VFs independently of the drug used to control acromegaly.
CONCLUSIONS: The rapid resolution of excessive GH led to the reversible changes of systemic comorbidities in a time-dependent and organ-specific manner. PMID: 29386229 [PubMed - as supplied by publisher]
SAN DIEGO, Jan. 30, 2018 -- (Healthcare Sales &Marketing Network) -- Dauntless Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of specialty therapeutics announces that the U.S. Food and Drug Administration (FD... Biopharmaceuticals, FDA Dauntless Pharmaceuticals, acromegaly